ARVN Q4 2023 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$43M-213.4% YoY

Gross Profit

-$45M103.9% margin

Operating Income

-$165M383.5% margin

Net Income

-$155M359.2% margin

EPS (Diluted)

$-2.53

QoQ Revenue Growth

-224.6%

Cash Flow

Operating Cash Flow

-$83M

Free Cash Flow

-$83M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$645M

Stockholders' Equity

$660M

Cash & Equivalents

$312M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$43M	$38M	-213.4%
Gross Profit	-$45M	$36M	-224.8%
Operating Income	-$165M	-$75M	-119.2%
Net Income	-$155M	-$83M	-86.7%